Literature DB >> 2019237

Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.

J J Couper1, I Hudson, G A Werther, G L Warne, J M Court, L C Harrison.   

Abstract

Twenty-five children aged 2-14 years (mean age 8.39 +/- 0.78 years) were studied prospectively during the first year after the diagnosis of type 1 diabetes. Of their clinical and metabolic features at diagnosis, only age showed a significant independent relationship with endogenous C-peptide production during the first year. Age was correlated with higher values for basal and stimulated plasma C-peptide at 7-14 days after diagnosis, at 6 months and at 12 months. At diagnosis, age was also associated with a higher value for HbA1c and a lower prevalence of insulin antibodies. C-peptide production peaked at 3 months and thereafter declined. Mean HbA1c and insulin requirement were both minimal at 6 months. At diagnosis, there were significant inverse relationships between basal C-peptide production and both insulin dose and HbA1c and between stimulated C-peptide production and HbA1c. Basal and stimulated C-peptide production were inversely related to insulin dose at 6 and 12 months. Stimulated C-peptide was higher at 12 months in children retaining islet cell antibodies. These findings confirm the importance of age as a predictor of residual beta-cell function in type 1 diabetes and indicate that older children present clinically following a slower course of beta cell destruction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019237     DOI: 10.1016/0168-8227(91)90135-z

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

Review 1.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

2.  Starting subcutaneous insulin doses in a paediatric population with newly diagnosed type 1 diabetes.

Authors:  Lisa Lemieux; Susan Crawford; Danièle Pacaud
Journal:  Paediatr Child Health       Date:  2010-07       Impact factor: 2.253

3.  CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes.

Authors:  Bruce Buckingham; Peiyao Cheng; Roy W Beck; Craig Kollman; Katrina J Ruedy; Stuart A Weinzimer; Robert Slover; Andrew A Bremer; John Fuqua; William Tamborlane
Journal:  Diabetologia       Date:  2015-03-14       Impact factor: 10.122

4.  Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.

Authors:  Kristin V Tarbell; Lucine Petit; Xiaopan Zuo; Priscilla Toy; Xunrong Luo; Amina Mqadmi; Hua Yang; Manikkam Suthanthiran; Svetlana Mojsov; Ralph M Steinman
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

5.  Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report.

Authors:  Harsha Moole; Vishnu Moole; Adrija Mamidipalli; Sowmya Dharmapuri; Raghuveer Boddireddy; Deepak Taneja; Hady Sfeir; Sonia Gajula
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-10-19

6.  Integration of Routine Parameters of Glycemic Variability in a Simple Screening Method for Partial Remission in Children with Type 1 Diabetes.

Authors:  Nina Nielens; Olivier Pollé; Annie Robert; Philippe A Lysy
Journal:  J Diabetes Res       Date:  2018-01-17       Impact factor: 4.011

7.  Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual β-cell function 1 year after diagnosis of type 1 diabetes.

Authors:  Marie Louise Max Andersen; Morten Arendt Rasmussen; Sven Pörksen; Jannet Svensson; Jennifer Vikre-Jørgensen; Jane Thomsen; Niels Thomas Hertel; Jesper Johannesen; Flemming Pociot; Jacob Sten Petersen; Lars Hansen; Henrik Bindesbøl Mortensen; Lotte Brøndum Nielsen
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.